To be honest, I really didn't understand the abstract, I want to see the presentation regarding how it works. There are some additional abstracts at the upcoming April conference looking at leukocyte migration as effected by checkpoint inhibitors. Totally off label, but certain types of lung cancer have like 5-8 year good survival data in 25-30 percent versus 4 percent survival with chemotherapy only. To be sure, this is in the subset of lung cancer patients who have the specific biomarker for checkpoint inhibitors. Still, marveling at the promise of immune therapy against cancer.
News 
Market Data 
Discover 
